Overview Dividends

(OPCH) Option Care Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68404L2016

Infusion Therapy, Nutrition Therapy, Immune Therapy, Nursing Services

OPCH EPS (Earnings per Share)

EPS Growth (3Y CAGR): 14.18%
EPS Trend (3Y Correlation): 19.7%

OPCH Revenue

Revenue Growth (3Y CAGR): 12.63%
Revenue Trend (3Y Correlation): 97.9%

Description: OPCH Option Care Health

Option Care Health Inc (NASDAQ:OPCH) is a healthcare services company specializing in home and alternate site infusion services across the United States. The company provides a broad range of infusion therapies and related services for various acute and chronic conditions, including infections, heart failures, nutritional deficiencies, immune deficiencies, inflammatory disorders, neurological disorders, bleeding disorders, and high-risk pregnancies.

Key areas of focus for OPCH include providing treatments for complex conditions such as cancer, gastrointestinal diseases, Crohns disease, rheumatoid arthritis, and multiple sclerosis. They also offer pain management, chemotherapy, and respiratory medication services. The companys services are marketed through referrals from healthcare professionals, hospitals, and health organizations.

From a performance perspective, OPCH has demonstrated a stable financial position, with a market capitalization of approximately $4.975 billion. The companys Return on Equity (ROE) stands at 15.29%, indicating a relatively strong ability to generate profits from shareholder equity. With a forward Price-to-Earnings (P/E) ratio of 20.53, OPCH appears to be reasonably valued compared to its expected earnings growth.

To further evaluate OPCHs potential, key performance indicators (KPIs) such as revenue growth rate, gross margin, operating margin, and debt-to-equity ratio should be examined. A high revenue growth rate and stable or expanding margins could indicate a strong operational performance. Additionally, a reasonable debt-to-equity ratio would suggest a manageable level of indebtedness. Other relevant metrics might include patient referral rates, customer satisfaction scores, and the companys ability to adapt to changing healthcare regulations and technologies.

OPCH Stock Overview

Market Cap in USD	4,747m
Sub-Industry	Health Care Services
IPO / Inception	1996-08-15

OPCH Stock Ratings

Growth Rating	5.84%
Fundamental	70.7%
Dividend Rating	-
Return 12m vs S&P 500	-24.8%
Analyst Rating	4.50 of 5

OPCH Dividends

Currently no dividends paid

OPCH Growth Ratios

Growth Correlation 3m	-78.7%
Growth Correlation 12m	20.4%
Growth Correlation 5y	63.5%
CAGR 5y	-4.02%
CAGR/Max DD 3y	-0.10
CAGR/Mean DD 3y	-0.34
Sharpe Ratio 12m	0.18
Alpha	-28.32
Beta	0.694
Volatility	31.08%
Current Volume	1626.1k
Average Volume 20d	1756.6k
Stop Loss	27.4 (-3.8%)
Signal	-0.79

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (211.3m TTM) > 0 and > 6% of Revenue (6% = 322.4m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 1.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 7.47% (prev 11.59%; Δ -4.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 279.6m > Net Income 211.3m (YES >=105%, WARN >=100%)

Net Debt (-198.8m) to EBITDA (408.3m) ratio: -0.49 <= 3.0 (WARN <= 3.5)

Current Ratio 1.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (165.4m) change vs 12m ago -4.99% (target <= -2.0% for YES)

Gross Margin 19.67% (prev 20.90%; Δ -1.23pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 159.7% (prev 137.1%; Δ 22.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.45 (EBITDA TTM 408.3m / Interest Expense TTM 53.1m) >= 6 (WARN >= 3)

Altman Z'' 2.60

(A) 0.12 = (Total Current Assets 1.18b - Total Current Liabilities 773.6m) / Total Assets 3.38b

(B) 0.23 = Retained Earnings (Balance) 766.6m / Total Assets 3.38b

(D) 0.38 = Book Value of Equity 773.6m / Total Liabilities 2.02b

Total Rating: 2.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.65

1. Piotroski 8.0pt = 3.0

2. FCF Yield 4.40% = 2.20

3. FCF Margin 4.66% = 1.16

4. Debt/Equity 0.83 = 2.16

5. Debt/Ebitda 2.78 = -1.43

6. ROIC - WACC 3.11% = 3.89

7. RoE 15.25% = 1.27

8. Rev. Trend 97.94% = 4.90

9. Rev. CAGR 12.63% = 1.58

10. EPS Trend 19.65% = 0.49

11. EPS CAGR 14.18% = 1.42

What is the price of OPCH shares?

As of September 14, 2025, the stock is trading at USD 28.48 with a total of 1,626,064 shares traded.
Over the past week, the price has changed by -2.10%, over one month by -0.21%, over three months by -10.64% and over the past year by -10.41%.

Is Option Care Health a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Option Care Health (NASDAQ:OPCH) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 70.65 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OPCH is around 23.46 USD . This means that OPCH is currently overvalued and has a potential downside of -17.63%.

Is OPCH a buy, sell or hold?

Option Care Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy OPCH.

Strong Buy: 6
Buy: 3
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OPCH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	38.8	36.2%
Analysts Target Price	38.8	36.2%
ValueRay Target Price	25.8	-9.3%

Last update: 2025-09-11 04:46

OPCH Fundamental Data Overview

Market Cap USD = 4.75b (4.75b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 198.8m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 23.2143
P/E Forward = 16.8634
P/S = 0.8833
P/B = 3.4907
P/EG = 1.6864
Beta = 0.826
Revenue TTM = 5.37b USD
EBIT TTM = 342.3m USD
EBITDA TTM = 408.3m USD
Long Term Debt = 1.10b USD (from longTermDebt, last quarter)
Short Term Debt = 29.8m USD (from shortTermDebt, last quarter)
Debt = 1.13b USD (Calculated: Short Term 29.8m + Long Term 1.10b)
Net Debt = -198.8m USD (from netDebt column, last quarter)
Enterprise Value = 5.68b USD (4.75b + Debt 1.13b - CCE 198.8m)
Interest Coverage Ratio = 6.45 (Ebit TTM 342.3m / Interest Expense TTM 53.1m)
FCF Yield = 4.40% (FCF TTM 250.3m / Enterprise Value 5.68b)
FCF Margin = 4.66% (FCF TTM 250.3m / Revenue TTM 5.37b)
Net Margin = 3.93% (Net Income TTM 211.3m / Revenue TTM 5.37b)
Gross Margin = 19.67% ((Revenue TTM 5.37b - Cost of Revenue TTM 4.32b) / Revenue TTM)
Tobins Q-Ratio = 7.34 (Enterprise Value 5.68b / Book Value Of Equity 773.6m)
Interest Expense / Debt = 1.47% (Interest Expense 16.7m / Debt 1.13b)
Taxrate = 25.31% (71.8m / 283.6m)
NOPAT = 255.7m (EBIT 342.3m * (1 - 25.31%))
Current Ratio = 1.52 (Total Current Assets 1.18b / Total Current Liabilities 773.6m)
Debt / Equity = 0.83 (Debt 1.13b / last Quarter total Stockholder Equity 1.36b)
Debt / EBITDA = 2.78 (Net Debt -198.8m / EBITDA 408.3m)
Debt / FCF = 4.53 (Debt 1.13b / FCF TTM 250.3m)
Total Stockholder Equity = 1.39b (last 4 quarters mean)
RoA = 6.24% (Net Income 211.3m, Total Assets 3.38b )
RoE = 15.25% (Net Income TTM 211.3m / Total Stockholder Equity 1.39b)
RoCE = 13.75% (Ebit 342.3m / (Equity 1.39b + L.T.Debt 1.10b))
RoIC = 10.24% (NOPAT 255.7m / Invested Capital 2.50b)
WACC = 7.13% (E(4.75b)/V(5.88b) * Re(8.57%)) + (D(1.13b)/V(5.88b) * Rd(1.47%) * (1-Tc(0.25)))
Shares Correlation 3-Years: -96.97 | Cagr: -0.92%
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.75% ; FCFE base≈228.1m ; Y1≈281.4m ; Y5≈480.2m
Fair Price DCF = 45.48 (DCF Value 7.38b / Shares Outstanding 162.3m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 97.94 | Revenue CAGR: 12.63%
Rev Growth-of-Growth: 4.87
EPS Correlation: 19.65 | EPS CAGR: 14.18%
EPS Growth-of-Growth: -13.22

Additional Sources for OPCH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle